Modern Approaches to Treating Rosacea in 2025
At the 2025 ODAC Dermatology Conference, renowned dermatologist and conference co-chair Adam Friedman, MD, delivered an insightful lecture, How I Treat Rosacea in 2025. He explored the latest advancements in managing one of dermatology’s most prevalent conditions, highlighting key triggers, associated comorbidities, and evolving treatment strategies. With global rosacea prevalence reported as hi …
At the 2025 ODAC Dermatology Conference, renowned dermatologist and conference co-chair Adam Friedman, MD, delivered an insightful lecture, How I Treat Rosacea in 2025. He explored the latest advancements in managing one of dermatology’s most prevalent conditions, highlighting key triggers, associated comorbidities, and evolving treatment strategies. With global rosacea prevalence reported as hi … Continue reading "Modern Approaches to Treating Rosacea in 2025"
Underrepresentation of patients with skin of color in clinical trials is an issue in medical research, including in research about dermatological conditions. A study in the January Journal of Drugs in Dermatology looked at the diversity of patients enrolled in melasma clinical trials to determine if there are any disparities in representation.
I interviewed author Jared Jagdeo, MD, MS, associat … 
At the forefront of the evolving treatment landscape for cutaneous squamous cell carcinoma (cSCC), Dr. David M. Miller—a board-certified internist, dermatologist, and medical oncologist at Massachusetts General Hospital—delivered a highly informative lecture on the past, present, and future of immunotherapy for cSCC at ODAC 2025. With his unique expertise across three disciplines, Dr. Miller e … 
The consumer press places a greater emphasis on cosmetic procedures in the winter months, and this year is no exception. Forbes wrote about new skincare treatments to try, including Sofwave, which uses ultrasound to stimulate collagen and elastin. Miria, a new fractionated, non-ablative skin tightening and resurfacing treatment, was featured for its safety in darker skin tones. The article also co … 
Atopic dermatitis and prurigo nodularis are chronic, life-altering diseases with a common feature of debilitating pruritus that significantly impacts our patients’ qualities of life. For those with resistant and extensive disease, dermatologists now have nemolizumab in our armamentarium, the first FDA approved IL-31 inhibitor. We continue our series, Therapeutic Cheat Sheet, with a closer look a … 